Clinical Outcomes of the Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Stent Versus Standard Drug-Eluting Coronary Stents: A Meta-Analysis
Highlights
- • Combo DTS vs. 2nd generation DES had higher 1-year target lesion revascularization.
- • No significant difference in 1-year: cardiac death, target lesion failure
- • No significant difference in 1-year: stent thrombosis, target vessel failure, and myocardial infarction
- • No significant difference in 2-year: cardiac death, target lesion failure, and target lesion revascularization
Abstract
Background
Coronary stent neoatherosclerosis, thrombosis, and restenosis remain significant concerns with new-generation drug-eluting stents (DES). The Dual-Therapy CD34 antibody-covered sirolimus-eluting stent [dual therapy stent (DTS)] is a sirolimus-eluting stent with CD34 antibodies immobilized on its luminal surface to capture circulating endothelial progenitor cells and promote early endothelialization. We conducted a meta-analysis to determine whether the DTS was superior to standard DES.